Rogério Vivaldi Coelho joined the Viatris board of directors in June 2024.
Career Highlights:
Dr. Vivaldi is the former President, Chief Executive Officer and Director of Sigilon Therapeutics, a diabetes cell therapy company. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ, Executive Vice President and Chief Commercial Officer at Spark Therapeutics, Chief Executive Officer and Director of Minerva Neurosciences, and, prior to that, held positions of increasing responsibility at Genzyme Corporation.
Key Skills and Experience:
Dr. Vivaldi’s qualifications to serve on the Board include, among others, his experience regarding public company management, corporate governance, the healthcare industry, finance, accounting, capital markets, risk oversight and compliance and strategy and M&A obtained over his many years in leadership positions in the healthcare industry, where he gained extensive experience leading and managing commercial, marketing and sales operations, managing patient access initiatives and leading the successful approval of innovative medicines. Dr. Vivaldi also brings human capital management and global business experience to the Board.
Other Current Public Company Boards:
- Crinetics Pharmaceuticals, Inc.
Former Public Company Boards:
- Sigilon Therapeutics, Inc.
- Minerva Neurosciences, Inc.
Former Private Company Boards:
- Spark Therapeutics, Inc.